Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership
Executive Summary
Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)
You may also be interested in...
Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb
The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested